ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 82 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,458 | +61.0% | 912 | +25.6% | 0.00% | – |
| Q1 2023 | $5,874 | – | 726 | +764.3% | 0.00% | – |
| Q1 2020 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 84 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | -99.0% | 84 | -99.2% | 0.00% | – |
| Q2 2018 | $199,000 | +40.1% | 9,903 | +22.7% | 0.00% | – |
| Q1 2018 | $142,000 | -28.3% | 8,068 | +0.0% | 0.00% | – |
| Q4 2017 | $198,000 | -2.9% | 8,066 | +2.1% | 0.00% | – |
| Q3 2017 | $204,000 | -18.4% | 7,900 | -14.3% | 0.00% | – |
| Q2 2017 | $250,000 | +14.7% | 9,220 | +26.0% | 0.00% | – |
| Q1 2017 | $218,000 | +73.0% | 7,320 | +57.8% | 0.00% | – |
| Q4 2016 | $126,000 | – | 4,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
| COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
| Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
| VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
| Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
| Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
| Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
| Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
| Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |